Leukemia patients who switched kinase inhibitors had favorable outcomes

Chronic lymphocytic leukemia patients who stopped taking the kinase inhibitors, ibrutinib or idelalisib, had mostly favorable outcomes when they switched to the alternate therapy, report investigators.